NEW FDA approval- Stemline Therapeutics
- December 28, 2018
- No responses
Stemline Therapeutics recently announced that the Food and Drug Administration (FDA) has approved ELZONRISTM (tagraxofusp-erzs; SL-401) for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): https://ir.stemline.com/news-releases/news-release-details/fda-approves-elzonristm-tagraxofusp-first-treatment-blastic
Full prescribing information can be found here:http://elzonris.com/hcp/resources/ELZONRIS_US_Full_Prescribing_Information.pdf
ELZONRISTM will not be available for shipment until late January. We are currently in the process of finalizing a compliment of clinical and patient focused resources. I’m available to schedule time to provide an overview of the product and answer questions you may have, either in person or remotely. Please let me know when a convenient time to connect or if there is someone else that I need to inform and I will arrange my schedule accordingly.